Aflibercept: all 271 studies that test it
Page 1 of 3. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.
- VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) StudyNot yet recruitingNCT07891182Phase 2
- A Study to Compare GNR-139 and Eylea® in Patients With nAMDRecruitingNCT07844148Phase 3
- Biomarkers, Effectiveness, and Safety of Aflibercept 8mg Modified Fixed Dose Regimen in Treatment-Naïve nAMD PatientsNot yet recruitingNCT07728981Early Phase 1
- A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular DegenerationRecruitingNCT07614776Phase 3
- Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS TrialRecruitingNCT07389980Phase 3
- Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular EdemaEnrolling by invitationNCT07338097Not applicable
- Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract SurgeryNot yet recruitingNCT07301775Phase 4
- Aflibercept and Bevacizumab for Diabetic MaculopathiesRecruitingNCT06850571Phase 4
- High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous VitrectomyRecruitingNCT06662994Phase 4
- Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal MelanomaRecruitingNCT06121180Phase 2
- Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic RetinopathyEnrolling by invitationNCT05296447Phase 2
- Plasma Biomarker for Aflibercept in Advanced Colorectal CancerRecruitingNCT04810585Phase 4
- A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)Active, not recruitingNCT06491914Phase 3Results posted
- Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)CompletedNCT05989126Phase 3Results posted
- A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)CompletedNCT05704725Phase 3Results posted
- A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular EdemaCompletedNCT05511038Phase 4Results posted
- A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of TreatmentTerminatedNCT05473715Phase 4Results posted
- Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial KitCompletedNCT05282004Phase 3Results posted
- Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled SyringeCompletedNCT05161806Phase 3Results posted
- Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular DegenerationCompletedNCT04864834Phase 3Results posted
- Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF TreatmentTerminatedNCT04707625Phase 4Results posted
- Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular DegenerationCompletedNCT04522167Phase 3Results posted
- Study of a High-Dose Aflibercept in Participants With Diabetic Eye DiseaseCompletedNCT04429503Phase 2/3Results posted
- A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]CompletedNCT04270747Phase 3Results posted
- A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular DegenerationCompletedNCT04200248Phase 2Results posted
- Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular DegenerationCompletedNCT04126317Phase 2Results posted
- Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of PrematurityCompletedNCT04101721Phase 3Results posted
- Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser TherapyCompletedNCT04004208Phase 3Results posted
- Study to Evaluate an Aflibercept (EYLEA®) Prefilled SyringeCompletedNCT03767738Phase 4Results posted
- Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal MelanomaTerminatedNCT03712904Phase 2Results posted
- Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also StudiedCompletedNCT03639675Phase 3Results posted
- IAI for Persistent DME After Treatment With Bevacizumab And RanibizumabCompletedNCT03340610Phase 4Results posted
- The IAI-OCTA Study; a Study of OCT-Angiography Analysis EfficacyCompletedNCT03022292Phase 4Results posted
- Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular EdemaCompletedNCT02949024Phase 1/2Results posted
- Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic RetinopathyCompletedNCT02863354Phase 2Results posted
- Anti-VEGF vs. Prompt Vitrectomy for VH From PDRCompletedNCT02858076Phase 2/3Results posted
- Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)CompletedNCT02818998Phase 3Results posted
- Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVOCompletedNCT02800642Phase 4Results posted
- Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)CompletedNCT02718326Phase 3Results posted
- Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular EdemaCompletedNCT02712008Phase 2Results posted
- EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept InjectionCompletedNCT02689518Phase 4Results posted
- Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) StudyCompletedNCT02661711Phase 2Results posted
- Anti-VEGF Treatment for Prevention of PDR/DMECompletedNCT02634333Phase 3Results posted
- Role of Intravitreal Aflibercept Injection for the Treatment of Radiation MaculopathyCompletedNCT02586727Phase 2Results posted
- Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.CompletedNCT02581995Phase 4Results posted
- Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the EyeCompletedNCT02581891Phase 4Results posted
- Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or BevacizumabCompletedNCT02559180Phase 4Results posted
- Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)CompletedNCT02540954Phase 3Results posted
- Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVOCompletedNCT02503540Phase 4Results posted
- IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMDCompletedNCT02462889Phase 2Results posted
- Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)TerminatedNCT02418754Phase 2Results posted
- Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma PatientsCompletedNCT02396316Phase 3Results posted
- A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)TerminatedNCT02387957Phase 2Results posted
- Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal CancersCompletedNCT02384759Phase 2Results posted
- Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DMECompletedNCT02363621Phase 2Results posted
- Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal CancerCompletedNCT02340949Phase 2Results posted
- Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular DegenerationCompletedNCT02305238Phase 4Results posted
- Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME TrialCompletedNCT02299336Phase 4Results posted
- Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular DegenerationCompletedNCT02257632Phase 4Results posted
- Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and SarcomasTerminatedNCT02192541Phase 1Results posted
- Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal CancerCompletedNCT02181556Phase 2Results posted
- Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT02159989Phase 1Results posted
- Aflibercept After Ranibizumab in Exudative Age-related Macular DegenerationCompletedNCT02157077Phase 3Results posted
- Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGFCompletedNCT02118831Phase 1/2Results posted
- Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT02101918Phase 2Results posted
- Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract SurgeryCompletedNCT01988246Phase 1/2Results posted
- Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)CompletedNCT01969708Phase 3Results posted
- Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer PatientTerminatedNCT01955629Phase 1/2Results posted
- Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal VasculopathyCompletedNCT01950741Phase 4Results posted
- Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular DegenerationCompletedNCT01926977Phase 1/2Results posted
- A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in JapanCompletedNCT01882868Phase 2Results posted
- Aflibercept Injection for Proliferative Diabetic RetinopathyCompletedNCT01805297Phase 2Results posted
- Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central InvolvementCompletedNCT01783886Phase 3Results posted
- Ziv-Aflibercept for Advanced Progressive Carcinoid TumorsCompletedNCT01782443Phase 2Results posted
- Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular DegenerationCompletedNCT01773954Not applicableResults posted
- 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal CancerCompletedNCT01749956Phase 2Results posted
- FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric CancerCompletedNCT01747551Phase 2Results posted
- Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)CompletedNCT01722045Phase 4Results posted
- Use of Intravitreal Aflibercept Injection for Neovascular GlaucomaCompletedNCT01711879Not applicableResults posted
- The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous ChorioretinopathyCompletedNCT01710332Phase 2Results posted
- Colorectal Cancer MetastaticCompletedNCT01670721Phase 3Results posted
- Adjuvant Aflibercept for Metastatic Colorectal CancerTerminatedNCT01669720Phase 2Results posted
- Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal CancerCompletedNCT01661972Phase 1/2Results posted
- A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin ChemotherapyCompletedNCT01661270Phase 3Results posted
- Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal CancerCompletedNCT01652196Phase 2Results posted
- Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular EdemaCompletedNCT01627249Phase 3Results posted
- Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to AfliberceptCompletedNCT01617148Phase 4Results posted
- Study for Recalcitrant Age Related Macular DegenerationCompletedNCT01543568Phase 4Results posted
- Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)CompletedNCT01521559Phase 3Results posted
- VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)CompletedNCT01482910Phase 3Results posted
- Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular EdemaCompletedNCT01363440Phase 3Results posted
- Intravitreal Aflibercept Injection in Vision Impairment Due to DMECompletedNCT01331681Phase 3Results posted
- Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT01258855Phase 2Results posted
- VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)CompletedNCT01249664Phase 3Results posted
- Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)CompletedNCT01012973Phase 3Results posted
- Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)CompletedNCT00964795Phase 3Results posted
- Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)CompletedNCT00943072Phase 3Results posted
- Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal CancerCompletedNCT00851084Phase 2Results posted
- S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT00828139Phase 2Results posted
- A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced CarcinomaTerminatedNCT00794417Phase 1/2Results posted